Lab Reagents
Human IgG antibody Laboratories manufactures the monoclonal antibodies to spike protein rbd reagents distributed by Genprice. The Monoclonal Antibodies To Spike Protein Rbd reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike RBD. Other Monoclonal products are available in stock. Specificity: Monoclonal Category: Antibodies Group: To Spike
To Spike information
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
10-303 |
ProSci |
0.1 mg |
EUR 632.4 |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2) |
100938-1 |
BPS Bioscience |
20 µg |
EUR 420 |
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa. |
Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2) |
100938-2 |
BPS Bioscience |
50 µg |
EUR 555 |
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa. |
Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2) |
100938-3 |
BPS Bioscience |
100 µg |
EUR 740 |
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa. |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Spike S1 RBD, His-tag (SARS-CoV-2) |
100687-1 |
BPS Bioscience |
50 µg |
EUR 410 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa. |
Spike S1 RBD, His-tag (SARS-CoV-2) |
100687-2 |
BPS Bioscience |
100 µg |
EUR 520 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa. |
Spike S1 RBD, Fc fusion (SARS-CoV-2) |
100699-1 |
BPS Bioscience |
50 µg |
EUR 410 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 RBD, Fc fusion (SARS-CoV-2) |
100699-2 |
BPS Bioscience |
100 µg |
EUR 520 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein |
20-232 |
ProSci |
0.1 mg |
EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein |
SARS-CoV-2 (COVID-19) Biotinylated Spike RBD Recombinant Protein |
10-205 |
ProSci |
0.1 mg |
EUR 752.1 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein |
10-304 |
ProSci |
0.1 mg |
EUR 632.4 |
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant |
P1530-10 |
Biovision |
10 µg |
EUR 187.2 |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant |
P1530-50 |
Biovision |
50 µg |
EUR 709.2 |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag |
E80024-1 |
EpiGentek |
100 ul |
EUR 635.8 |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag |
E80024-2 |
EpiGentek |
1 ml |
EUR 4995.1 |